Empowered Funds LLC Boosts Stock Position in Edwards Lifesciences Corporation $EW
Empowered Funds LLC boosted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 154. 6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,019 shares of the me
Empowered Funds LLC boosted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW-Free Report) by 154. 6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,019 shares of the medical research company's stock after buying an additional 49,800 shares during the period. Empowered Funds LLC's holdings in Edwards Lifesciences were worth $6,568,000 at the end of the most recent reporting period. A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHOther large investors have also added to or reduced their stakes in the company. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter worth $266,000. NewEdge Advisors LLC raised its position in shares of Edwards Lifesciences by 8. 1% in the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company's stock worth $2,787,000 after purchasing an additional 2,665 shares during the last quarter. Sei Investments Co. raised its position in shares of Edwards Lifesciences by 16. 7% in the 2nd quarter. Sei Investments Co. now owns 412,808 shares of the medical research company's stock worth $32,285,000 after purchasing an additional 58,988 shares during the last quarter. Squarepoint Ops LLC boosted its stake in Edwards Lifesciences by 277. 7% in the 2nd quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company's stock worth $5,417,000 after purchasing an additional 50,924 shares in the last quarter. Finally, Treasurer of the State of North Carolina boosted its stake in Edwards Lifesciences by 0. 4% in the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company's stock worth $21,028,000 after purchasing an additional 1,065 shares in the last quarter. Hedge funds and other institutional investors own 79. 46% of the company's stock. GetEdwards Lifesciencesalerts:Edwards Lifesciences Stock PerformanceShares ofEWopened at $91. 51 on Friday. The business has a 50-day simple moving average of $88. 73 and a two-hundred day simple moving average of $84. 37. The company has a quick ratio of 3. 77, a current ratio of 4. 52 and a debt-to-equity ratio of 0. 06. Edwards Lifesciences Corporation has a 52 week low of $72. 30 and a 52 week high of $96. 29. The stock has a market cap of $52. 69 billion, a price-to-earnings ratio of 52. 59, a PEG ratio of 2. 30 and a beta of 0. 85. Beyond Biotech—3 Healthcare Stocks for Growth-Minded InvestorsEdwards Lifesciences (NYSE:EW-Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0. 78 earnings per share for the quarter, beating analysts' consensus estimates of $0. 74 by $0. 04. The firm had revenue of $1. 74 billion for the quarter, compared to analysts' expectations of $1. 70 billion. Edwards Lifesciences had a return on equity of 15. 68% and a net margin of 15. 43%. The business's quarterly revenue was up 13. 6% on a year-over-year basis. During the same period in the previous year, the firm earned $0. 67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0. 710-0. 770 EPS and its FY 2026 guidance at 2. 950-3. 050 EPS. On average, analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year. Wall Street Analyst Weigh InSeveral analysts recently commented on EW shares. JPMorgan Chase & Co. increased their price objective on shares of Edwards Lifesciences from $100. 00 to $105. 00 and gave the company an "overweight" rating in a research report on Friday, July 24th. Evercore reiterated an "outperform" rating and issued a $100. 00 target price on shares of Edwards Lifesciences in a research note on Monday, July 6th. Leerink Partners upgraded shares of Edwards Lifesciences from a "market perform" rating to an "outperform" rating and increased their price target for the company from $87. 00 to $101. 00 in a report on Friday, July 24th. Royal Bank Of Canada raised their price target on shares of Edwards Lifesciences from $100. 00 to $110. 00 and gave the company an "outperform" rating in a research report on Monday, July 13th. Finally,Wall Street Zenlowered shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Saturday, July 4th. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat. com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $100. 27. 3 Healthcare Pathbreakers With Long-Term TailwindsRead Our Latest Research Report on Edwards LifesciencesInsiders Place Their BetsIn other Edwards Lifesciences news, VPDaniel J. Lippissold 619 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92. 03, for a total transaction of $56,966. 57. Following the transaction, the vice president owned 40,034 shares of the company's stock, valued at $3,684,329. 02. The trade was a 1. 52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available throughthe SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VPDonald E. Bobo, Jr. sold 23,145 shares of the company's stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86. 42, for a total transaction of $2,000,190. 90. Following the completion of the transaction, the vice president owned 98,611 shares of the company's stock, valued at approximately $8,521,962. 62. The trade was a 19. 01% decrease in their ownership of the stock. TheSEC filingfor this sale provides additional information. In the last 90 days, insiders have sold 26,190 shares of company stock worth $2,269,697. Company insiders own 0. 31% of the company's stock. About Edwards Lifesciences(Free Report)Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery. In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams. Featured StoriesFive stocks we like better than Edwards LifesciencesIs Best Buy the AI Winner Hiding in the Electronics Aisle?Applied Materials Beat Everything but Wall Street’s Expectations for MarginsBack From Orbit, Intuitive Machines' Share Price Enters the Buy ZoneTexas Roadhouse and Brinker International Have the Recipe Rivals Are MissingThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat. com. Continue following MarketBeatAdd MarketBeat as your preferred source on Google to see our latest stories in your feed. Should You Invest $1,000 in Edwards Lifesciences Right Now?Before you consider Edwards Lifesciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified thefive stocksthat top analysts are quietly whispering to their clients to buy now before the broader market catches on. . . and Edwards Lifesciences wasn't on the list. While Edwards Lifesciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks HereClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report